Complete response to immunotherapy in sinonasal undifferentiated carcinoma

Abstract

Sinonasal undifferentiated carcinoma (SNUC) is an uncommon aggressive tumor. Locally advanced disease is usually diagnosed at presentation. Multidisciplinary approach is essential and aims to ensure optimal trimodal strategy. Induction chemotherapy is preferred in order to select patients who will benefit from chemoradiotherapy or surgery. Immunotherapy is not indicated in patients with recurrent SNUC. We describe an impressive response in a young man previously treated with radiotherapy and chemotherapy and demolitive surgery who had metastatic bone and lung disease. We also report data on PD-L1, next-generation sequencing, and neutrophil/platelets ratio.

Durable and Dramatic Response to Checkpoint Inhibition Combined with IDO1 Inhibitor Celecoxib in a Patient with p16+ Metastatic Sinonasal Undifferentiated Carcinoma

“…To our knowledge, this case is the first report of a response of metastatic SNUC to PD-1/CTLA-4 checkpoint inhibitors in combination; overcoming resistance to single agent pembrolizumab. A recent case report detailed the successful use of immunotherapy to treat a patient with metastatic SNUC [4]. However, in contrast to the current case, that case involved the use of a single-agent checkpoint inhibitor, nivolumab.…”

Durable and dramatic response to checkpoint inhibition combined with COX‐2 inhibitor celecoxib in a patient with p16+ metastatic sinonasal undifferentiated carcinoma: A case study

“…To our knowledge, this case is the first report of a response of metastatic sinonasal undifferentiated carcinoma to PD‐1/CTLA‐4 checkpoint inhibitors in combination, overcoming resistance to single agent pembrolizumab. A recent case report detailed the successful use of immunotherapy to treat a patient with metastatic SNUC 6 . However, in contrast to the current case, that case involved the use of a single‐agent checkpoint inhibitor, nivolumab.…”

Sinonasal NUT carcinoma: A consecutive case series and systematic review

“…7,21 In other aggressive sinonasal malignancies, including SNUC, using neoadjuvant chemotherapy response as a guide for treatment has been found to improve survival. 8,21,22 In patient populations not restricted to those with sinonasal tumors, BRD4-NUTM1 fusions appear to portend a worse prognosis than non-BRD4-NUTM1 fusions (BRD3-or NSD3-NUTM1), regardless of metastatic involvement. 23 This testing was not consistently available in our population.…”